Gyre Therapeutics
GYRE
46 hedge funds and large institutions have $47M invested in Gyre Therapeutics in 2020 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 18 increasing their positions, 11 reducing their positions, and 11 closing their positions.
64% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 11
11% more call options, than puts
Call options by funds: $492K | Put options by funds: $445K
0.25% more ownership
Funds ownership: 8.36% → 8.61% (+0.25%)
0% more funds holding
Funds holding: 46 → 46 (0)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
0% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 11
9% less capital invested
Capital invested by funds: $51.4M → $47M (-$4.42M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACP
Acuta Capital Partners
Redwood City,
California
|
+$8.48M |
| 2 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$4.36M |
| 3 |
Millennium Management
New York
|
+$2.33M |
| 4 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$2.3M |
| 5 |
JGC
J. Goldman & Co
New York
|
+$2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MP
Mangrove Partners
Greenwich,
Connecticut
|
-$4.65M |
| 2 |
Marshall Wace
London,
United Kingdom
|
-$855K |
| 3 |
D.E. Shaw & Co
New York
|
-$422K |
| 4 |
WG
Winton Group
London,
United Kingdom
|
-$290K |
| 5 |
FM
Fondren Management
Houston,
Texas
|
-$272K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
GCP
51
GSA Capital Partners
London,
United Kingdom
| – | -$232K | -4,540 | Closed |
|
|
ARTA
52
A.R.T. Advisors
New York
| – | -$150K | -2,930 | Closed |
|
|
EMG
53
Ellington Management Group
Old Greenwich,
Connecticut
| – | -$129K | -2,520 | Closed |
|
54
JP Morgan Chase
New York
| – | -$102K | -1,992 | Closed |
|
|
MWNA
55
Marshall Wace North America
New York
| – | -$96K | -1,889 | Closed |
|
56
Barclays
London,
United Kingdom
| – | -$4.96K | -108 | -96% |
|
|
PCM
57
Prelude Capital Management
New York
| – | -$5K | -107 | Closed |
|
GYRE Hedge Fund Activity: Q1 2020 in Review
46 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in Gyre Therapeutics (GYRE) for Q1 2020, worth a combined $47M — down 8.6% from $51.4M a quarter earlier.
Fund positioning in GYRE was balanced in Q1 2020: 11 funds opened new positions, 11 closed out, 18 added to existing stakes and 11 trimmed.
The largest buyer was Acuta Capital Partners, opening a new position worth an estimated $8.48M. The largest seller was Mangrove Partners, exiting entirely with an estimated $4.65M sold.
- 46 institutional investors held Gyre Therapeutics (GYRE) as of Q1 2020, unchanged from Q4 2019.
- Funds reported $47M of Gyre Therapeutics stock for Q1 2020, down 8.6% quarter-over-quarter.
- 11 funds opened new Gyre Therapeutics positions in Q1 2020 and 11 closed out, a net change of 0 holders.
- The largest Gyre Therapeutics buyer in Q1 2020 was Acuta Capital Partners, an estimated $8.48M added.
- The largest Gyre Therapeutics seller in Q1 2020 was Mangrove Partners, an estimated $4.65M sold.
Based on aggregated 13F filings for Q1 2020.